Patents by Inventor David A. Engers

David A. Engers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200095127
    Abstract: A method for the manufacture of crystal water-free iron(II) orthophosphate of the general formula Fe3(PO4)2 or crystal water-free iron(II) metal orthophosphate, iron(II) metal pyrophosphate or iron(II) metal metaphosphate of the general formula FeaMetb(POc)d, where a is a number from 1 to 5, b is a number from >0 to 5, c is a number from 2.5 to 5, d is a number from 0.5 to 3 and Met represents one or more metals selected from the group consisting of K, Rb, Cs, Mg, Ca, Sr, Ba, the transition metals (d block), in particular Sc, Y, La, Ti, Zr, Hf, Nb, Ta, Cr, Mo, W, Mn, Cu, Zn and the metals and semimetals of the third, fourth and fifth main groups, in particular B, Al, Ga, In, Si, Sn, Sb, Bi and the lanthanoids.
    Type: Application
    Filed: March 26, 2018
    Publication date: March 26, 2020
    Applicant: Chemische Fabrik Budenheim KG
    Inventors: Joachim ADOLF, Dominik BRAUN, Gerhard EICH, David ENGERS, Bastian EWALD, Christian LITTERSCHEID, Rüdiger WISSEMBORSKI
  • Publication number: 20200039934
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: March 11, 2019
    Publication date: February 6, 2020
    Inventors: Anthony Alexander MCKINNEY, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Patent number: 10280141
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 7, 2019
    Assignee: OTSUKA AMERICA PHARMACEUTICAL, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Publication number: 20180194726
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: November 21, 2017
    Publication date: July 12, 2018
    Inventors: Anthony Alexander MCKINNEY, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Patent number: 9856217
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: January 2, 2018
    Assignee: NEUROVANCE, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Publication number: 20170334850
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: June 1, 2017
    Publication date: November 23, 2017
    Inventors: Anthony Alexander MCKINNEY, Franklin BYMASTER, Walter PISKORSKI, Fred J. FLEITZ, Yonglai YANG, David A. ENGERS, Valeriya SMOLENSKAYA, Venkat KUSUKUNTLA
  • Patent number: 9708261
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: July 18, 2017
    Assignee: NEUROVANCE, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Publication number: 20160368871
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: June 17, 2016
    Publication date: December 22, 2016
    Inventors: Anthony Alexander MCKINNEY, Franklin BYMASTER, Walter PISKORSKI, Fred J. FLEITZ, Yonglai YANG, David A. ENGERS, Valeriya SMOLENSKAYA
  • Publication number: 20160136148
    Abstract: The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10. Another solid dispersion contains amorphous paroxetine mesylate and a-vinylpyrrolidone/vinylacetate copolymer (PVP-VA), where the weight ratio of paroxetine mesylate to copolymer ranges from about 30:70 to about 50:50. An amorphous solid dispersion of the invention may have a single glass transition temperature. An amorphous solid dispersion is stable for at least 48 hours at 60° C. and 75% relative humidity. A further embodiment of the invention relates to pharmaceutical compositions of paroxetine mesylate comprising a solid dispersion of the invention and at least one pharmaceutically acceptable excipient.
    Type: Application
    Filed: November 10, 2015
    Publication date: May 19, 2016
    Applicant: NOVEN THERAPEUTICS, LLC
    Inventors: David A. Engers, Yonglai Yang, Stephen Parent, Travis Houston, Bruce Charles Friedman
  • Patent number: 9211290
    Abstract: The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10. Another solid dispersion contains amorphous paroxetine mesylate and a -vinylpyrrolidone/vinylacetate copolymer (PVP-VA), where the weight ratio of paroxetine mesylate to copolymer ranges from about 30:70 to about 50:50. An amorphous solid dispersion of the invention may have a single glass transition temperature. An amorphous solid dispersion is stable for at least 48 hours at 60° C. and 75% relative humidity. A further embodiment of the invention relates to pharmaceutical compositions of paroxetine mesylate comprising a solid dispersion of the invention and at least one pharmaceutically acceptable excipient.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 15, 2015
    Assignee: NOVEN THERAPEUTICS, LLC
    Inventors: David A. Engers, Yonglai Yang, Stephan Parent, Travis Houston, Bruce Charles Friedman
  • Publication number: 20140194510
    Abstract: The subject invention provides a solid dispersion of rasagiline citrate, a composition and a process for the manufacture thereof.
    Type: Application
    Filed: March 10, 2014
    Publication date: July 10, 2014
    Applicant: Teva Pharmaceutical Industries Ltd.
    Inventors: Keith Lorimer, David Engers
  • Publication number: 20140187582
    Abstract: The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10. Another solid dispersion contains amorphous paroxetine mesylate and a -vinylpyrrolidone/vinylacetate copolymer (PVP-VA), where the weight ratio of paroxetine mesylate to copolymer ranges from about 30:70 to about 50:50. An amorphous solid dispersion of the invention may have a single glass transition temperature. An amorphous solid dispersion is stable for at least 48 hours at 60° C. and 75% relative humidity. A further embodiment of the invention relates to pharmaceutical compositions of paroxetine mesylate comprising a solid dispersion of the invention and at least one pharmaceutically acceptable excipient.
    Type: Application
    Filed: March 15, 2013
    Publication date: July 3, 2014
    Inventors: David A. ENGERS, Yonglai YANG, Stephan PARENT, Travis HOUSTON, Bruce Charles FRIEDMAN
  • Patent number: 8691872
    Abstract: The subject invention provides a solid dispersion of rasagiline citrate, a composition and a process for the manufacture thereof.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: April 8, 2014
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Keith Lorimer, David Engers
  • Publication number: 20130158264
    Abstract: Polymorphic forms of the tyrosine kinase inhibitor OSI-906, preparation, pharmaceutical compositions, and uses thereof. The invention includes methods of treating diseases such as cancer, including cancer mediated at least in part by IGF-1 R and/or IR, with the polymorphs and compositions. This Abstract is not limiting of the invention.
    Type: Application
    Filed: June 23, 2011
    Publication date: June 20, 2013
    Inventors: Arlindo L. Castelhano, David A. Enger, Jason A. Hanko, Josef A. Rechka, Jing Teng, Yonglai Yang
  • Publication number: 20120190817
    Abstract: The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I.
    Type: Application
    Filed: July 12, 2011
    Publication date: July 26, 2012
    Applicant: Celgene Corporation
    Inventors: Jason Hanko, David Engers, Eric Hagen, Valeriya Smolenskaya, Jeffrey Stults
  • Publication number: 20120059058
    Abstract: The subject invention provides a solid dispersion of rasagiline citrate, a composition and a process for the manufacture thereof.
    Type: Application
    Filed: July 27, 2011
    Publication date: March 8, 2012
    Inventors: Keith Lorimer, David Engers
  • Patent number: 6221400
    Abstract: The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increased rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HIV-2) protease inhibitors are described.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: April 24, 2001
    Assignee: Elan Pharma International Limited
    Inventors: Gary G. Liversidge, David A. Engers, Mary E. Roberts, Stephen B. Ruddy, Sui-Ming Wong, Shuqian Xu
  • Patent number: 6068858
    Abstract: The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increased rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HV-2) protease inhibitors are described.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: May 30, 2000
    Assignee: Elan Pharma International Limited
    Inventors: Gary G. Liversidge, David A. Engers, Mary E. Roberts, Stephen B. Ruddy, Sui-Ming Wong, Shuqian Xu
  • Patent number: 6045829
    Abstract: The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increase rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HIV-2) protease inhibitors are described.
    Type: Grant
    Filed: July 9, 1997
    Date of Patent: April 4, 2000
    Assignee: Elan Pharma International Limited
    Inventors: Gary G. Liversidge, David A. Engers, Mary E. Roberts, Stephen B. Ruddy, Sui-Ming Wong, Shuqian Xu
  • Patent number: 5571536
    Abstract: Nanoparticulate crystalline drug substances formulated in an aqueos phase emulsified in oil, are able to be made at less than 1000 nm size and provide increased bioavailability and lymphatic uptake following oral administration.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: November 5, 1996
    Assignee: Nano Systems L.L.C.
    Inventors: W. Mark Eickhoff, Karl R. Mueller, David A. Engers